Clinical Trial Details
| Trial ID: | L1234 |
| Source ID: | NCT00294866 |
| Associated Drug: | Paricalcitol |
| Title: | Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Kidney Failure |
| Interventions: | DRUG: Paricalcitol |
| Outcome Measures: | Primary: Primary Outcome is a 20% change in IL-6 as a function of paricalcitol therapy., 4 weeks | Secondary: Secondary Outcome is a significant change in markers of inflammation to include:, 4 weeks|CRP,TNFα, IL-1β, IL-8, IL-10, IL-12p70, PTH, Ca/P, 4 weeks |
| Sponsor/Collaborators: | Sponsor: Fresenius Medical Care North America | Collaborators: Abbott |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 64 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION |
| Start Date: | 2006-03 |
| Completion Date: | 2008-01 |
| Results First Posted: | |
| Last Update Posted: | 2010-04-08 |
| Locations: | Southwest Nephrology, Evergreen Park, Illinois, 60805, United States|Nephrology Center, Kalamazoo, Michigan, 49007, United States|Nephrology Associates P.A., West Orange, New Jersey, 07052, United States|Delaware Valley Nephrology, Philadelphia, Pennsylvania, 19144, United States|Nephrology Associates, PC, Nashville, Tennessee, 37205, United States|Tyler Nephrology Associates, Tyler, Texas, 75701, United States |
| URL: | https://clinicaltrials.gov/show/NCT00294866 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|